SHH · 603259.SS
WuXi AppTec Co., Ltd.
CN¥142.01-CN¥0.88 (-0.62%)
WuXi AppTec Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 18.2% below the high.
Loading market information…
HKSE · 9877.HK · HKD
Stock price, earnings
Quote as of Oct 30, 2026, 08:08 AM UTC. Cached market data; not a live quote.
One-year closing-price history · HKD. Historical prices are not a forecast.
Jenscare Scientific Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 45.16% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Jenscare Scientific Co., Ltd.’s next earnings report is currently expected on Mar 31, 2027. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Jenscare Scientific Co., Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Jenscare Scientific Co., Ltd. operates as a medical technology enterprise dedicated to advancing interventional therapies for structural heart conditions within the People's Republic of China. Among its pipeline, the company features LuX-Valve, an investigational transcatheter tricuspid valve replacement (TTVR) system designed for patients suffering from severe tricuspid regurgitation who face elevated surgical risks. Additionally, Ken-Valve represents another key product candidate, a transcatheter aortic valve replacement (TAVR) aimed at addressing severe aortic regurgitation, often co-occurring with aortic stenosis. The applications of Jenscare's portfolio extend to a range of structural cardiac maladies, including disorders of the tricuspid, aortic, and mitral valves, as well as heart failure. Founded in 2011, the company maintains its principal place of business in Ningbo, People's Republic of China.
Latest available per-share figures in HKD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 11:57 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
CN¥142.01-CN¥0.88 (-0.62%)
WuXi AppTec Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 18.2% below the high.
CN¥48.46-CN¥0.16 (-0.33%)
Jiangsu Hengrui Medicine Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 26.39% below the high.
HK$50.70+HK$0.05 (+0.1%)
Jiangsu Hengrui Pharmaceuticals Co.,Ltd’s quoted price sits in the lower half of its reported 52-week range, 37.37% below the high.
HK$1.47-HK$0.08 (-5.16%)
LifeTech Scientific Corporation’s quoted price sits in the lower half of its reported 52-week range, 38.24% below the high.
HK$13.15-HK$1.10 (-7.72%)
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 33.59% below the high.
HK$3.77-HK$0.15 (-3.83%)
Peijia Medical Limited’s quoted price sits in the lower half of its reported 52-week range, 48.85% below the high.
HK$0.98HK$0.00 (0.0%)
Venus Medtech (Hangzhou) Inc.’s quoted price sits in the lower half of its reported 52-week range, 74.61% below the high.
HK$0.93-HK$0.04 (-3.63%)
Shanghai Bio-heart Biological Technology Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 89.43% below the high.
